Kornimate/medical-research-clean huggingface dataset:
maximal use systemic exposure (muse) study of levulan kerastick

Conditions: Keratosis, Actinic

Summary: the purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ala) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (ak) involving the upper extremities.


Eligibility criteria:
inclusion criteria: * at least 6 grade 1/2 aks on one upper extremity and * at least 12 grade 1/2 aks on the other upper extremity exclusion criteria: * pregnancy * history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis * lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the treatment area * body mass index (bmi) \> 32.0 kg/m2 * skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy * significant blood loss within 60 days or donated blood/plasma within 72 hours prior to visit 2 (baseline) * tested positive at screening for human immunodeficiency virus (hiv) or was known to be seropositive for hiv * a history of lead poisoning or a history of a significant exposure to lead or a screening lead level above 6μg/dl * tested positive at screening for hepatitis b surface antigen, hepatitis c antibody or had a history of a positive result * positive drug screen at screening * screening safety labs are clinically significant in the opinion of the investigator * major surgery within 30 days prior to visit 2 (baseline) or plans to have surgery during the study * subject is immunosuppressed * currently enrolled in an investigational drug or device study * has received an investigational drug or been treated with an investigational device within 30 days prior to visit 2 (baseline) * known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol) * use of the following topical preparations on the extremities to be treated: * keratolytics including urea (greater than 5%), alpha hydroxyacids \[e.g.glycolic acid, lactic acid, etc. greater than 5%\], salicylic acid (greater than 2%) within 2 days of initiation of treatment * cryotherapy within 2 weeks of initiation of treatment * retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of initiation of treatment * microdermabrasion, laser ablative treatments, ala-pdt, chemical peels, 5-fu, diclofenac, imiquimod or other topical treatments for ak within 8 weeks of initiation of treatment * use of systemic retinoid therapy within 6 months of initiation of treatment

Keywords: actinic keratosis
telerehabilitation for post covid-19 condition

Conditions: Long COVID; Chronic Fatigue Syndrome

Summary: telerehabilitation is a great alternative to offering care during a global pandemic. 85% of patients with covid-19 report persistent symptoms up to 8 months after the infection. there are no clear recommendations for post-covid rehabilitation. the aims of the study are (1) to test the logistic aspect of implanting a hybrid rehabilitation program and (2) to evaluate the acceptability and the potential impact of the program on treating patients with functional limitations and persistent fatigue symptoms. it's a pre and post-study without a control group.

telerehabilitation is a great alternative to offering care during a global pandemic. 85% of patients with covid-19 report persistent symptoms up to 8 months after the infection. there are no clear recommendations for post-covid rehabilitation. the aims of the study are (1) to test the logistic aspect of implanting a hybrid rehabilitation program and (2) to evaluate the acceptability and the potential impact of the program on treating patients with functional limitations and persistent fatigue symptoms. it's a pre and post-study without a control group. the intervention will be based on cardiopulmonary rehabilitation principles and will be administered for 12 weeks. fatigue, post-exertional malaise, and functional/exercise capacities will be evaluated.

Eligibility criteria:
inclusion criteria: * living in the community * living near sherbrooke (\<50km) * having a diagnostic of covid-19 confirmed (pcr) and post-covid syndrome (according to the world health organization criteria) * being aged between 25 and 65 years old * having access to internet at home * living with a family member/caregiver or having a telephone or a medical alert system (in case of emergency) * reporting persistent fatigue symptoms according to the fatigue severity scale (fss) (score≥4/7) * reporting functional limitations according to the post-covid-19 functional status scale (pcfs (score ≥2/4); * being able to give free and informed consent (adequate understanding of the study protocol); * agreeing to perform a pulmonary function test, an exercise stress test, and an ergospirometric exercise test (adequate understanding of steps and procedures); * having a low exercise capacity and moderate-to-severe cardiovascular risk \<7 metabolic equivalent of a task (met) or ≤9 if significant reduction of self-reported exercise tolerance according to the stress test performed on a treadmill - cornell protocol); * having no other potential explanatory causes for fatigue or reduced exercise capacity according to medical evaluation exclusion criteria: * cognitive impairment: mini-mental state examination (mmse) ≤24/30 * inability to perform or understand study procedures * medical contraindication

Keywords: cardiorespiratory exercise virtual rehabilitation post covid-19 syndrome fatigue physiotherapy post-covid affection post-covid condition
survey on the characteristics of traditional medicine syndromes in urticaria patients at le van thinh hospital

Conditions: Urticaria

Summary: this study aims to investigate the characteristics of traditional medicine (tm) syndromes in urticaria patients at le van thinh hospital. urticaria is a common dermatological condition that significantly impacts patients' quality of life. however, there is limited research on tm syndrome classification in this patient group. the study will collect data on symptoms, tm syndromes, and disease severity to determine common syndromes and their associations with clinical manifestations. the study will be conducted as a cross-sectional, observational study with an estimated 200 participants. eligible patients are those aged 18 years or older, diagnosed with acute or chronic urticaria, and willing to participate. the primary outcomes include the prevalence of tm syndromes, itching severity measured by the visual analogue scale (vas), and the correlation between tm syndromes and itching severity. the study is approved by the institutional review board (irb) of the university of medicine and pharmacy at ho chi minh city and will be conducted from december 2024 to april 2025 at le van thinh hospital, vietnam.


Eligibility criteria:
inclusion criteria: * patients aged 15 years or older. * diagnosed with acute or chronic urticaria based on modern medical criteria. * willing to participate and provide informed consent. exclusion criteria: * patients with other dermatological conditions that may interfere with the diagnosis of urticaria. * patients currently using medications that may alter symptom presentation (e.g., antihistamines, corticosteroids, immunosuppressants). * patients who refuse to participate in the study
measuring the impact of a multimodal intervention on falls and fear falls among people 65 years old, residents at home

Conditions: Fall; Old Age; Atrophy

Summary: measuring the impact of a multimodal intervention on falls and fear falls among people 65 years old, residents at home in boulogne city

we hypothesize that participation in the multimodal program " autonomy prevention kit " would lead to a decrease in falls and the fear of falling. this study targets retired people, 65 years of age and over, living at home, identified as being independent (iso group resources type 4-5-6 without formal validation being carried out) but who represent statistically an increased risk of falls in comparison to the general population. the inclusion takes place before the first session of the equilibr'age® workshop. subjects will have already benefited from a first collective information organized by the boulogne city council (see annexes of the crf). 3 times mark the collection of data. at the time of inclusion, at the end of the 12 sessions of the equilbr'age® workshop (m3) and 3 months after the end of the workshop ( 6 months after the beginning of inclusion). the study does not involve new acts since it is only an assessment of the effects of a protocol that proposes non-sports activities as well as advice to citizens of the municipality.

Eligibility criteria:
inclusion criteria: * retired * age ≥ 65 years; * gir ≥ 4 * commitment to participate in all interventions of the "autonomy prevention" kit * autonomous in its travels * the person expressed no objection to participating in the kitpa study. exclusion criteria: * in professional activity * age \< 65 years; * gir \< 4 * person under guardianship or curatorship
exercise for patients with hiv infections

Conditions: HIV Infections; Lipodystrophy; Inflammation

Summary: the investigators will evaluate the effects of an endurance exercise program on the physical performance, the well being, and indicators of metabolic function in patients with an hiv infection.


Eligibility criteria:
inclusion criteria: * age 18 to 65 * hiv infection * antiviral therapy * understanding of written german exclusion criteria: * diabetes mellitus * all conditions which can be aggravated by exercise

Keywords: hiv exercise inflammation quality of life lipodystrophia
healing, equity, advocacy and respect for mamas

Conditions: Postpartum Complication

Summary: the goal of the proposed research is to test the comparative effectiveness of aim safety bundles for post-partum women delivered in-person vs. via text/phone to improve early detection of and timely care for complications during the first six weeks postpartum for women experiencing significant health disparities.

the purpose of the study is to learn if a program for newborn mom's can improve detection of complications after delivery and help women get medical care quickly and easily. participants will be asked to complete a survey at the time of enrollment and at 3 additional times. all surveys can be completed via cell-phone or email. all women will be followed for 1-year after delivery. women that enroll will be assigned to one of two groups: usual in person care or usual in-person care plus a text message-based program that will ask about sign and symptoms of complications that may occur after delivery. if there is a concern, a nurse advocate will call on the phone to discuss options and help refer to care if needed. participants will be paid for their time in completing surveys.

Eligibility criteria:
inclusion criteria for postpartum women * postpartum woman within approximately 2 weeks of delivering a baby of gestational age ≥ 26 weeks in south carolina. * aged 16-49 years old. * insured by medicaid. exclusion criteria for postpartum women * plans to relocate outside of sc anytime during the postpartum year. * plans to discontinue medicaid health insurance during the postpartum year. * speaks a language other than english or spanish. * incarcerated/pending incarceration during peripartum period. * currently institutionalized. * enrolled in current musc study funded by pcori (#pro00123833) * does not have and/or does not wish to use their personal cell phone for the study. inclusion criteria for obstetric providers and hospital administrators - ob provider working at a delivery hospital in sc and directly involved in the care of postpartum women; or hospital administrator working in a delivery hospital in sc and job responsibilities relate to the postpartum unit. exclusion criteria for obstetric providers and hospital administrators * less than 1 month of hear 4 mamas experience if involved in the hospital where participants are recruited from. * unable or unwilling to commit to completing surveys or an interview. * speaking a language other than english.

Keywords: aim (alliance for innovation on maternal health) safety bundles randomized controlled trial (rct) emergency department (ed) visits shared decision making (sdm) patient-reported outcomes (pros) patient stakeholder group (psg) study advisory committee (sac)
molecular regulation of muscle glucose metabolism

Conditions: Obesity; Type 2 Diabetes Mellitus

Summary: this protocol is being conducted to determine the mechanisms responsible for insulin resistance, obesity and type 2 diabetes.

this protocol involves performance of a hyperinsulinemic euglycemic clamp with 2 muscle biopsies and an exercise study with a muscle biopsy.

Eligibility criteria:
inclusion criteria: 1. subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent. 2. subjects may be of either sex, age as described in each protocol. female subjects must be non-lactating and must either be at least two years post-menopausal, (if diabetic or obese) or be using adequate contraceptive precautions (i.e. oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal ligation, bilateral oophorectomy). female patients (except for those patients who have undergone a hysterectomy or bilateral oophorectomy) are eligible only if they have a negative pregnancy test throughout the study period. 3. subjects must range in age as described in each specific protocol. 4. all nondiabetic subjects must have normal oral glucose tolerance. 5. subjects must have the following laboratory values: 1. hematocrit ≥ 35 vol% 2. serum creatinine ≤ 1.6 mg/dl 3. aspartate aminotransferase (ast) (sgot) \< 2 times upper limit of normal 4. alanine aminotransferase (alt) (sgpt) \< 2 times upper limit of normal 5. alkaline phosphatase \< 2 times upper limit of normal 6. triglycerides \< 150 mg/dl. 7. prothrombin time (pt) 11.7 -14.3 (during liposyn/heparin infusion, pt will be determined to insure that it is \< 1.5-2.0 times the normal value.) 8. partial thromboplastin time (ptt) 23.0-37.0. exclusion criteria: 1. subjects must not be receiving any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on stable dose of such agents for the past three months before entry into the study. subjects may be taking a stable dose of estrogens or other hormonal replacement therapy, if the subject has been on these agents for the prior three months. subjects taking systemic glucocorticoids are excluded. 2. subjects with a history of clinically significant heart disease (new york heart classification greater than grade ii; more than non-specific st-t wave changes on the ekg), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) will not be studied. 3. recent systemic or pulmonary embolus, untreated high-risk proliferative retinopathy, recent retinal hemorrhage, uncontrolled hypertension, systolic bp \> 180, diastolic bp \> 105, autonomic neuropathy, resting heart rate \> 100, electrolyte abnormalities.

Keywords: insulin resistance mitochondria
a phase i/ii double-blind safety and efficacy evaluation of nowarta110 in patients with plantar warts

Conditions: Plantar Warts

Summary: to evaluate drug safety and efficacy in patients treated with nowarta110 and to determine therapeutic activity against plantar warts * clinical tolerance * clinical recovery * evaluate safety

plantar warts occur on the soles (plantar surface of feet) and can be severely debilitating for patients even for normal walking. the severity and magnitude of the warts can vary, but they are the cause of much pain and discomfort for all age groups. nowarta 110 has been evaluated for the therapy of plantar warts caused by the hpv virus, (hpv infection). clinical experience in a totals of 124 patients receiving nowarta 110 for 5 weeks treatment in multiple clinics overseas has demonstrated the potential of nowarta110 with absolutely no side effect.

Eligibility criteria:
inclusion criteria: * patients with refractory or recurrent plantar warts. * no wart treatment for the last 12 weeks * healthy male or non-pregnant, non-lactating female aged ≥ 18 years or greater * if female of childbearing potential, use an acceptable form of birth control during the study * provide written informed consent or (hipaa consent/authorization, as applicable exclusion criteria: * concurrent medical disorder or disease making implementation or interpretation of the protocol or results difficult or unsafe * female subjects who are breast-feeding or planning to become pregnant * patients with a history of allergy to silver or fruits * subjects with clinically significant unstable medical disorder, life threatening disease, or current malignancies * subjects with history of alcohol abuse or other drug abuse within 2 years prior to randomization * subjects who have been treated with an investigational drug or investigational device within a period of 30 days prior to study enrollment * concomitant medications: any other wart therapy is prohibited during the study.
study of medical assistant health coaching in primary care for patients with chronic conditions

Conditions: Diabetes; Hypertension; Hyperlipidemia

Summary: randomized control trial studying the effect of medical assistant health coaching for patients with diabetes, hypertension and hyperlipidemia within two san francisco primary care community clinics, mission neighborhood health center and southeast health center


Eligibility criteria:
inclusion criteria: active patients at mission neighborhood health center, sf, usa or southeast health center, sf, usa age 18-75 years uncontrolled diabetes ii, hypertension or hyperlipidemia spanish or english speaking exclusion criteria: cognitive dysfunction, mental health or physical condition that prevents participation in health coaching.
postoperative nasal high flow versus oxygen for positive airway pressure non-compliance sleep apnea patients

Conditions: Obstructive Sleep Apnea

Summary: the study aims to compare the efficacy of nasal high flow therapy (nhf) with low-flow oxygen supplementation in improving postoperative intermittent desaturations. if so, this mode of therapy would provide a cost effective, relatively easy to implement, and better tolerated treatment to continuous positive airway pressure (cpap) for oxygen stabilization.

patients identified preoperatively with previously diagnosed obstructive sleep apnea (intermittent collapse of upper airway while asleep) who refuse continuous positive airway pressure use after surgery and are treated with routine postoperative supplemental oxygen alone (1 liters per minute) will have more oscillation of oxygen saturation during the night (measure by overnight oximetry) than those treated with high nasal flow air insufflator (fisher \& paykel airvo 2 device) with same amount of oxygen supplement (1 liters per minute).

Eligibility criteria:
inclusion criteria: 1. known diagnosis of obstructive sleep apnea by polysomnography (apnea hypopnea index ≥ 5 events per hour) with recommendation of continuous positive airway pressure use. 2. the patient declines use of continuous positive airway pressure for the upcoming elective surgery. 3. the patient will require more than 48 hours of hospitalization. 4. informed consent obtained from patient or approved designate. exclusion criteria: 1. predetermined need for continuous positive airway pressure post-operatively by surgical team. 2. body mass index ≥ 40. 3. patient with congestive heart failure and diagnosis of cheyne- stokes respiration or central apnea. 4. patients who are oxygen dependent due to moderate to severe chronic obstructive pulmonary disease (available forced expiratory volume at 1 second of \< 50% predicted) or advanced interstitial lung disease. 5. preexisting chronic hypercapnia with known neuromuscular disease with respiratory involvement (e.g. amyotrophic lateral sclerosis, myopathy). 6. severe anemia necessitating blood transfusion. 7. presence of tracheostomy. 8. naso-oral malformation or severe nasal septal defect. 9. presence of dementia or other diagnosed neurodegenerative disease. 10. non-english speakers 11. inability to provide informed consent.
imagery-based cbt for social anxiety disorder: piloting a treatment augmentation protocol

Conditions: Social Anxiety Disorder

Summary: the purpose of this pilot study is to explore whether there is a differential impact of verbal versus imagery-based cognitive behavioural therapy (cbt) as a treatment augmentation strategy for individuals with social anxiety disorder (sad). clients who have not demonstrated clinically significant change following group cbt for sad will receive four additional sessions of either verbal-based cbt or imagery-based cbt. we hypothesize that that individuals who receive imagery-based cbt will experience even stronger improvements and be more satisfied with their treatment than individuals who received traditional verbal-linguistic cbt.

social anxiety disorder (sad) is a debilitating disorder, marked by significant functional impairment and high personal distress for those who suffer. psychological treatment for sad has traditionally been verbal-linguistic cognitive behavioural therapy (cbt). however, a significant number of individuals who complete cbt for sad do not achieve full response and continue to struggle with significant residual symptoms. one innovation that has received attention recently in the literature is using imagery-based cbt as a way to augment treatment outcome in sad. results from a pilot and benchmarking study suggest that participants who received imagery-based cbt were more likely to complete treatment than those who received traditional cbt and treatment outcome was strong for both groups, but stronger in the imagery-based cbt group. however, before re-training hundreds of practitioners in using a completely novel treatment approach, it is important to see if a brief augmentation of traditional cbt programs is effective in producing further change for individuals with residual symptoms after group cbt. it is possible that individuals just require a few more sessions of the same verbal-linguistic cbt to consolidate treatment gains or work on lingering triggers of anxiety. it is also possible that more of the same is not as valuable as offering therapy using a different modality, such as imagery. therefore, we propose to evaluate a brief imagery-based augmentation of traditional group cbt to explore its effects on further symptom reduction.

Eligibility criteria:
inclusion criteria: * completed eight out of twelve sessions of standard verbal-linguistic group cognitive behavioural therapy for social anxiety disorder * presented with a social phobia inventory (spin) score of greater than 19 post-treatment * interested in further treatment exclusion criteria: * has another mental health concern of greater importance than social anxiety disorder

Keywords: cognitive behavioural therapy